Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug.

The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat ...

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Repatha sales beat the Zacks Consensus Estimate of $555.0 million and our model estimate of $542.9 million. While 2024 sales were impacted by price erosion, in 2025, Amgen expects less price ...

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...